SUBSEQUENT EVENTS |
6 Months Ended |
---|---|
Jun. 30, 2016 | |
Notes to Financial Statements | |
Note 18 - SUBSEQUENT EVENTS |
Effective July 5, 2016, the Company amended its articles of incorporation to increase the authorized shares of capital stock of the Company from two hundred million (200,000,000) shares of common stock and eighty thousand (80,000) shares of preferred stock, both $.001 par value respectively, to five hundred twenty five million (525,000,000) shares common stock, and six hundred thousand (600,000) shares of preferred stock, both $.001 par value respectively.
In July 2016, the Company issued 700,000 shares of its common stock for consulting services.
Effective July 28, 2016, the Company entered into a Development, Commercialization and License Agreement with TheraKine Ltd. The Company was granted an exclusive worldwide license to utilize the Technology in developing injectable naltrexone products to treat patients suffering from addiction to opioids, methamphetamines, cocaine, or alcohol. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. No definition available.
|